TSHA
NASDAQ · Biotechnology
Taysha Gene Therapies Inc
$6.56
+0.22 (+3.47%)
Open$6.45
Previous Close$6.34
Day High$6.57
Day Low$6.35
52W High$7.30
52W Low$2.63
Volume—
Avg Volume2.51M
Market Cap2.10B
P/E Ratio—
EPS$-0.38
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+827.7% upside
Current
$6.56
$6.56
Target
$60.86
$60.86
$45.99
$60.86 avg
$68.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.96M | 6.96M | 242.81M |
| Net Income | -122,065,952 | -69,738,689 | 41.01M |
| Profit Margin | -1,115.3% | -1,059.5% | 16.9% |
| EBITDA | -122,459,829 | -73,850,591 | 60.77M |
| Free Cash Flow | — | — | 46.40M |
| Rev Growth | +57.5% | +57.5% | -6.9% |
| Debt/Equity | 0.20 | 0.20 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |